UNLIMITED TURBO BULL - ASTRAZENECA | Real-time Euronext Paris 03:09:33 2024-06-20 EDT | ||
| 1.405 EUR | +2.55% |
|
| Current month | +13.69% | ||
| 1 month | +18.10% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-20 | 1.405 | +2.55% |
| 24-06-19 | 1.37 | -5.19% |
| 24-06-18 | 1.445 | -2.36% |
| 24-06-17 | 1.48 | -7.50% |
| 24-06-14 | 1.6 | +11.89% |
Real-time Euronext Paris
Last update June 20, 2024 at 03:09 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| 3J14S | |
| ISIN | DE000SW9Q6K9 |
| Date issued | 2024-04-30 |
| Strike | 11,217 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.29 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.81 € |
|---|---|
| Lowest since issue | 0.89 € |
| Spread | 0.1 € |
| Spread % | 6.76% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157
USD
Average target price
174.4
USD
Spread / Average Target
+11.09%
- Stock Market
- Certificates
- 3J14S Certificat
